Gastroenterology Unit, Ospedale V Cervello, Palermo, Italy.
Aliment Pharmacol Ther. 2014 May;39(10):1180-93. doi: 10.1111/apt.12721. Epub 2014 Mar 24.
Morphological, haemodynamic and clinical stages of cirrhosis have been proposed, although no definite staging system is yet accepted for clinical practice.
To investigate whether clinical complications of cirrhosis may define different prognostic disease stages.
Analysis of the database from a prospective inception cohort of 494 patients. Decompensation was defined by ascites, bleeding, jaundice or encephalopathy. Explored potential prognostic stages: 1, compensated cirrhosis without oesophago-gastric varices; 2, compensated cirrhosis with varices; 3, bleeding without other complications; 4, first nonbleeding decompensation; 5, any second decompensating event. Patient flow across stages was assessed by a competing risks analysis.
Major patient characteristics were: 199 females, 295 males, 404 HCV+, 377 compensated, 117 decompensated cirrhosis. The mean follow-up was 145 ± 109 months without dropouts. Major events: 380 deaths, 326 oesophago-gastric varices, 283 ascites, 158 bleeding, 146 encephalopathy, 113 jaundice, 126 hepatocellular carcinoma and 19 liver transplantation. Patients entering each prognostic stage along the disease course were: 202, stage 1; 216, stage 2; 75 stage 3; 206 stage 4; 213 stage 5. Five-year transition rate towards a different stage, for stages 1-4 was 34.5%, 42%, 65% and 78%, respectively (P < 0.0001); 5-year mortality for stages 1-5 was 1.5%, 10%, 20%, 30% and 88% respectively (P < 0.0001). An exploratory analysis showed that this patient stratification may configure a prognostic system independent of the Child-Pugh score, Model for End Stage Liver Disease and comorbidity.
The development of oesophago-gastric varices and decompensating events in cirrhosis identify five prognostic stages with significantly increasing mortality risks.
尽管目前尚无明确的临床分期系统被广泛接受,但已经提出了肝硬化的形态学、血流动力学和临床分期。
探讨肝硬化的临床并发症是否可以定义不同的预后疾病分期。
分析前瞻性起始队列的 494 例患者的数据库。失代偿定义为腹水、出血、黄疸或肝性脑病。探讨潜在的预后分期:1. 无食管胃静脉曲张的代偿性肝硬化;2. 有静脉曲张的代偿性肝硬化;3. 无出血的并发症;4. 首次非出血性失代偿;5. 任何第二次失代偿事件。通过竞争风险分析评估患者在各期之间的流动情况。
主要患者特征为:女性 199 例,男性 295 例,丙型肝炎病毒感染 404 例,377 例代偿性肝硬化,117 例失代偿性肝硬化。平均随访时间为 145±109 个月,无失访。主要事件:380 例死亡,326 例食管胃静脉曲张,283 例腹水,158 例出血,146 例肝性脑病,113 例黄疸,126 例肝细胞癌和 19 例肝移植。患者在疾病过程中进入每个预后阶段的情况如下:202 例进入第 1 期,216 例进入第 2 期,75 例进入第 3 期,206 例进入第 4 期,213 例进入第 5 期。第 1-4 期向不同阶段的 5 年转换率分别为 34.5%、42%、65%和 78%(P<0.0001);第 1-5 期的 5 年死亡率分别为 1.5%、10%、20%、30%和 88%(P<0.0001)。一项探索性分析表明,这种患者分层可能构成一种独立于 Child-Pugh 评分、终末期肝病模型和合并症的预后系统。
食管胃静脉曲张和失代偿事件的发展可将肝硬化分为五个预后阶段,各阶段的死亡率风险显著增加。